Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer

Description

The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor progression.

Conditions

Lung Neoplasms

Talk to us

Study Overview

On this page

Study Details

Study overview

The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor progression.

Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers

Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer

Condition
Lung Neoplasms
Intervention / Treatment

-

Contacts and Locations

Aurora

University of Colorado Cancer Center, Aurora, Colorado, United States, 80045

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patients undergoing investigation or treatment for thoracic cancers with oncogene-targeted therapies
  • 2. Aged 18 years or older
  • 3. Either a) have suspected tumor progression or other condition that dictates a standard-of-care palliative, therapeutic, or diagnostic intervention including but not limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS) pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor specimen appropriate molecular analysis or b) have previously had biopsy/surgical intervention with tumor tissue at University of Colorado or an outside institution available for medullar analysis.
  • 4. Patients must have the ability to understand and willingness to sign an informed consent document.

Ages Eligible for Study

18 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Colorado, Denver,

Robert C. Doebele, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

2027-01-30